Benjamin Edwards’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$32.6K Buy
10,671
+342
+3% +$1.14K ﹤0.01% 1448
2026
Q2
$38.1K Sell
10,329
-3,523
-25% -$11.7K ﹤0.01% 1417
2026
Q1
$48.2K Buy
+13,852
New +$52.7K ﹤0.01% 1350
2025
Q2
– Sell
-21,101
Closed -$42K – 1200
2025
Q1
$42K Sell
21,101
-820
-4% -$2.09K ﹤0.01% 1072
2024
Q4
$63.9K Sell
21,921
-1,275
-5% -$4.48K ﹤0.01% 1098
2024
Q3
$89.6K Buy
23,196
+23,010
+12,371% +$107K ﹤0.01% 1076
2024
Q2
$1K Sell
186
-121
-39% -$734 ﹤0.01% 696
2024
Q1
$2K Sell
307
-7
-2% -$53 ﹤0.01% 694
2023
Q4
$3K Sell
314
-7
-2% -$54 ﹤0.01% 618
2023
Q3
$3K Hold
321
– – ﹤0.01% 614
2023
Q2
$5K Buy
321
+139
+76% +$1.94K ﹤0.01% 610
2023
Q1
$2K Buy
182
+35
+24% +$570 ﹤0.01% 667
2022
Q4
$3K Buy
+147
New +$2.66K ﹤0.01% 663

Other funds holding PRME

Benjamin Edwards's PRME Position: Q3 2026 in Review

Benjamin Edwards increased its Prime Medicine (PRME) stake by 3.3% in Q3 2026, buying an estimated $1.14K and bringing the position to 10,671 shares worth $32.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1448.

Benjamin Edwards first reported a position in PRME in Q4 2022 and has held it in 13 quarters since. The position peaked at $89.6K in Q3 2024. 125 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Benjamin Edwards held 10,671 shares of Prime Medicine worth $32.6K as of Q3 2026.
  • Benjamin Edwards bought 342 Prime Medicine shares in Q3 2026, an estimated $1.14K.
  • Prime Medicine made up ﹤0.01% of Benjamin Edwards's portfolio in Q3 2026, its #1448 holding.
  • Benjamin Edwards first reported a position in Prime Medicine in Q4 2022 and has held it in 13 quarters since.
  • Benjamin Edwards's Prime Medicine position peaked at $89.6K in Q3 2024.
  • 125 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Benjamin Edwards's 13F filing for Q3 2026, filed 12 Nov 2026.